Note to the businessman

Note to the businessman

In the Shadow of Theranos

The venture business is still experiencing the consequences of the most scandalous collapse in the recent history of the biotech market.

26.03.2019

Note to the businessman

Rejuvenation Startups

Today, the field of rejuvenation biotechnology has infinite potential in terms of opportunities to create new startups.

04.03.2019

Note to the businessman

Biotech-2019: where to invest?

In 2019, the profitability of investments in bioengineering will largely depend on the developments described in this article.

29.01.2019

Note to the businessman

A patent is not a dogma

An algorithm has been developed that allows finding ways to synthesize pharmacological drugs bypassing patent restrictions.

23.01.2019

Note to the businessman

Investments in anti-aging

The latest market estimates show a new trend – more and more investors are making a serious bet on the anti-age industry.

07.12.2018

Note to the businessman

Digital Medicine

The concept of "telemedicine" has appeared recently, although it can include telephone consultations with a familiar doctor, and an ambulance call.

05.12.2018

Note to the businessman

Medicine-2019

The main trends in global healthcare in the coming year are artificial intelligence systems and blockchain.

16.11.2018

Note to the businessman

Genes for money

Worldwide, consumer genomics is growing at a record pace. What problems do Russian scientists and investors face?

06.11.2018

Note to the businessman

Won't investors fly by?

In 2018, biotech startups in the United States raised almost $6 billion. And statistics show that promises are rarely implemented.

02.11.2018

Note to the businessman

Who should I go to?

Who invests in biotechnological projects in Russia and how to attract the attention of large investors?

01.10.2018

Note to the businessman

At the cellular level

Those who want to invest in new medicines should think carefully about how to avoid major mistakes and choose promising ideas.

01.06.2018

Note to the businessman

DNA as medicine

The market of cell and gene therapy will be actively developing in the coming years, and the average annual sales growth will be at least 30%.

29.05.2018

Note to the businessman

Bigfarma's beastly grin

Is it profitable for pharmaceutical companies to cure patients? An analyst at one of the largest investment banks believes that no.

19.04.2018

Note to the businessman

The stingy rich

With very few exceptions, rich people do not fund rejuvenation research. They age and die, just like the rest of us.

20.03.2018

Note to the businessman

Animal Biotechnology – 2018

In the ResearchAndMarkets online store, you can buy an overview of "Animal Biotechnology – technologies, markets and companies".

13.02.2018

Note to the businessman

Personalized Medicine – 2018

The review "Personalized Medicine – Scientific and commercial aspects" has been put on sale.

12.02.2018

Note to the businessman

Bet on chemistry

Jakafi has made Incyte's shares one of the most sought-after on Wall Street, and the company itself has been the subject of endless takeover gossip.

06.02.2018

Note to the businessman

Biotech Stars

Buying small biotech startups means growth for the entire industry, but will pharmaceutical companies invest more actively in such enterprises?

24.01.2018

Note to the businessman

Pharmacy for venture

A venture investor in biotech has two ways to secure his investments: to buy more expensive at late stages or to reduce risks on his own.

16.01.2018

Note to the businessman

Venture Biotech

How biotechnologists learn to "hack microorganisms" and why investors invested almost $1 billion in such startups last year.

15.01.2018